Table 2 Summary of results of clinical trials with combinations of anti-PD-1/PD-L1 with immunotherapy
Study name/code (NCT) | Study phase | Type of Cancer | Treatment | Patients evaluated for response | Time to first tumor assessment (weeks) | ORR by RECIST 1.1 criteria | ORR by immune-related response criteria | Patients treated beyond progression | Response rate after initial PD | First author and date of publication |
|---|---|---|---|---|---|---|---|---|---|---|
102,323 (NCT02523469) | 1b | NSCLC | Nivolumab plus ALT-803 [IL-15 superagonist] | 21 | 6 | 6 (28.6%) | Not reported | Not reported | 1 (4.8%) | Wrangle 2018 [69] |
ABC (NCT02374242) | 2 | Melanoma | Nivolumab plus ipilimumab | 35 | 12 | 16–17 (46–57%)a | Not reported | 21 (60.0%) | 4 (11.4%) | Long 2018 [70] |
Alliance A091401 (NCT02500797) | 2 | Sarcoma | Nivolumab plus ipilimumab | 38 | 6 | 6 (15.8%) | Not reported | 8 (21.1%) | 1 (2.6%) | D’Angelo 2018 [16] |
CheckMate-004 (NCT01024231) | 1 | Melanoma | Nivolumab plus ipilimumab | 52 | 8 | 21 (40.4%) | Not reported | Not reported | 4 (7.7%) | Wolchock 2013 [24] |
CheckMate 032 (NCT01928394) | 1/2 | Small-cell lung carcinoma | Nivolumab plus ipilimumab | 118 | 6 | 25 (21.2%) | Not reported | 21 (17.8%) | Not reported | Antonia 2016 [30] |
CheckMate-067 (NCT01844505) | 3 | Melanoma | Nivolumab plus ipilimumab | 314 | 12 | 183 (58.3%) | Not reported | 62 (19.8%) | Not reported | Wolchok 2017 [36] |
D4190C00006 (NCT02000947) | 1b | NSCLC | Durvalumab plus tremelimumab | 63 | 8 | 11 (17.5%) | Not reported | Not reported | 2 (3.2%) | Antonia 2016 [71] |
J1L-AM-JZGA (NCT02009449) | 1b | Advanced solid tumours | Pegilodecakin plus anti-PD-1 | 96 | 8 | Not reported | 29 (30.2%) | Not reported | Not reported | Naing 2019 [72] |
NIBIT-MESO-1 (NCT02588131) | 2 | Mesothelioma | Durvalumab plus tremelimumab | 40 | 12 | Not reported | 11 (27.5%) | 13 (32.5%) | 1 (2.5%) | Calabrò 2018 [73] |